12-Dec-2025
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
PRNewswire (Tue, 9-Dec 11:58 AM ET)
Market Chameleon (Thu, 6-Nov 4:34 AM ET)
Schrdinger to Present at Jefferies London Healthcare Conference
Business Wire (Thu, 6-Nov 8:30 AM ET)
Schrdinger Reports Third Quarter 2025 Financial Results
Business Wire (Wed, 5-Nov 4:05 PM ET)
Business Wire (Thu, 30-Oct 7:30 AM ET)
Schrdinger to Announce Third Quarter 2025 Financial Results on November 5
Business Wire (Wed, 22-Oct 8:30 AM ET)
Schrdinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Wed, 15-Oct 8:30 AM ET)
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
Schrodinger trades on the NASDAQ stock market under the symbol SDGR.
As of December 12, 2025, SDGR stock price declined to $18.05 with 903,932 million shares trading.
SDGR has a beta of 1.85, meaning it tends to be more sensitive to market movements. SDGR has a correlation of 0.27 to the broad based SPY ETF.
SDGR has a market cap of $1.32 billion. This is considered a Small Cap stock.
Last quarter Schrodinger reported $54 million in Revenue and -$.57 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.16.
In the last 3 years, SDGR traded as high as $59.24 and as low as $15.99.
The top ETF exchange traded funds that SDGR belongs to (by Net Assets): IJR, VTI, ARKG, VB, IWM.
SDGR has underperformed the market in the last year with a return of -14.3%, while the SPY ETF gained +14.0%. In the last 3 month period, SDGR fell short of the market, returning -2.8%, while SPY returned +4.0%. However, in the most recent 2 weeks SDGR has outperformed the stock market by returning +2.8%, while SPY returned -0.2%.
SDGR support price is $17.54 and resistance is $18.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SDGR shares will trade within this expected range on the day.
